Serum ALT levels as a surrogate marker for serum HBV DNA levels in HBeAg-negative pregnant women

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 3, 2004, Pages 182-185

  Sangfelt, Per ^a   Von Sydow, Madeline ^b   Uhnoo, Ingrid ^a   Weiland, Ola ^b   Lindh, Gudrun ^b   Fischler, Björn ^b   Lindgren, Susanne ^b   Reichard, Olle ^c,d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CARRIER; DISEASE MARKER; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL DEPARTMENT; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY; RETROSPECTIVE STUDY; SCREENING TEST; SENSITIVITY ANALYSIS; SWEDEN; VIROLOGY; VIRUS REPLICATION;

ADULT; ALANINE TRANSAMINASE; BASE SEQUENCE; BIOLOGICAL MARKERS; CARRIER STATE; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DISEASE TRANSMISSION, VERTICAL; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; INFANT, NEWBORN; MASS SCREENING; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PRENATAL CARE; PROBABILITY; REFERENCE VALUES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; STATISTICS, NONPARAMETRIC; SWEDEN;

EID: 2442443165     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410027111     Document Type: Article

References (24)

1. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292(15): 771-4.
2. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, Chen CL. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2(8359): 1099-102.
3. Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989; 1(8635): 406-10.
4. del Canho R, Grosheide PM, Schalm SW, de Vries RR, Heijtink RA. Failure of neonatal hepatitis B vaccination: the role of HBV DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol 1994; 20(4): 483-6.
5. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994; 170(6): 1418-23.
6. del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WC, Gerards LJ, et al. 10-y neonatal hepatitis B vaccination programme, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997; 15(15): 1624-30.
7. Hadziyannis S. Hepatitis B e antigen-negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1: 7-36.
8. Funk ML, Rosenberg DM, Lok AS. Worldwide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9(1): 52-61.
9. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 2000; 7(4): 258-67.
10. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38(3): 619-28.
11. Bacq Y, Zarka O, Brechot JF, Mariotte N, Vol S, Tichet J, Weill J. Liver function tests in normal pregnancy: a prospective study of 103 pregnant women and 103 matched controls. Hepatology 1996; 23(5): 1030-4.
12. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36(6): 1408-15.
13. Soderstrom A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis 2003; 35(11-12): 817-9.
14. WHO. WHO expanded programme on immunization. Report of 14th Global Advisory Group. Antalya, Turkey; 1991 Oct 14-18.
15. Iwarson S. Why the Scandinavian countries have not implemented universal vaccination against hepatitis B. Vaccine 1998; 16 (Suppl): S56-7.
16. Beasley RP, Hwang LY, Lin CC, Stevens CE, Wang KY, Sun TS, et al. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomized double-blind placebo-controlled trial. Lancet 1981; 2(8243): 388-93.
17. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000: summary of a workshop. Gastroenterology 2001; 120(7): 1828-53.
18. Rosendahl C, Kochen MM, Kretschmer R, Wegscheider K, Kaiser D. Avoidance of perinatal transmission of hepatitis B virus: is passive immunization always necessary? Lancet 1983; 1(8334): 1127-9.
19. Esteban JI, Genesca J, Esteban R, Hernandez JM, Seijo G, Buti M, et al. Immunoprophylaxis of perinatal transmission of the hepatitis B virus: efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area. J Med Virol 1986; 18(4): 381-91.
20. Milne A, West DJ, Chinh DV, Moyes CD, Poerschke G. Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J Med Virol 2002; 67(3): 327-33.
21. Yang YJ, Liu CC, Chen TJ, Lee MF, Chen SH, Shih HH, Chang MH. Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. Pediatr Infect Dis J 2003; 22(7): 584-8.
22. Sangfelt P, Reichard O, Lidman K, von Sydow M, Forsgren M. Prevention of hepatitis B by immunization of the newborn infant: a long- term follow-up study in Stockholm, Sweden. Scand J Infect Dis 1995; 27(1): 3-7.
23. Soderstrom A, Norkrans G, Conradi N, Krantz M, Horal P, Lindh M. Histological activity of childhood chronic hepatitis B related to viraemia levels, genotypes, mutations, and epidemiological factors. J Pediatr Gastroenterol Nutr 2002; 35(4): 487-94.
24. ACIP. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991; 40: 1-19.